ClinicalTrials.gg
Not yet recruitingNCT06913959OBSOCAMUpdated Oct 29, 2026

HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)

An observational study in HIV Infection, sponsored by ANRS, Emerging Infectious Diseases. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by ANRS, Emerging Infectious Diseases · Observational

How we know

Updated Oct 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
220
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases — 12 open to participants now, 13 under way, none of them phase 3. HIV Infections · ANRS, Emerging Infectious Diseases.

Planned enrollment
13th of 22
220 · median 488
Started
2026
with 2 others
Observational
22 of 73
7 open now
Primary completion
2027-07
later than 8 of 12 live
Registered
70th of 73
by date

Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 13th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2026, is one of 22 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 70th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.

Read the detailed description

HIV-1 is divided four distinct groups: M (major) which represents the pandemic strains while others groups O (outlier), N (non M, non O) and P are called non-M variants. Group O (HIV-O) is more divergent, endemic in Central Africa and Cameroon, where it represents about 1% of HIV infections. These variants are characterized by an important genetic divergence from pandemic HIV-1 group M (HIV-M), which impacts on the diagnosis, monitoring and treatment of infected patients. Although discovered in 1990, and emerged at the same time as HIV-M, no data of epidemiology, natural history and evolution of the genetic diversity of these variants is currently available. The few knowledge available to date come from sporadic cases, mainly through studies in Yaoundé. It is therefore essential to improve current knowledge on these variants and their consequences on infected patients.

The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • HIV genetic diversity
  • HIV-1 non-M variants
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Retrospective phase : Dried Blood Spot samples tested positive for HIV during the Demographic health surveys in Cameroon 2011 and 2018 surveys, serotyping for HIV.

Prospective phase : Individuals who came to Center Pasteur Cameroon in Yaoundé or Garoua for HIV screening or viral load monitoring, serotyping of HIV for positive samples.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All available samples tested positive for during the national Health survey of Cameroon in 2011 And 2018
  • All Individuals who came to Centre Pasteur in Yaoundé or Garoua for HIV screening or viral load monitoring.

Exclusion criteria

Exclusion Criteria:

  • Insufficient quantity or degraded Dried Blood Spot samples
  • All -positive individuals aged less than 21 years, infected with a Group M HIV-1 virus, or those who refused to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
220 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Retrospective

    Dried Blood Spot samples tested positive for HIV during the previous national epidemiologic surveys Demographic health surveys in Cameroon

    Diagnostic Test: Prospective

  • Prospective

    Individuals who came to Center Pasteur in Yaounde or Garoua for HIV screening or viral load monitoring

    Diagnostic Test: Prospective

Interventions

  • Diagnostic testProspective

    Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research

06

What researchers measure

Primary outcomes

  1. Prevalence of non-M HIV-1 in Cameroon

    Number of participants infected with non-M HIV-1 included compared to the total expected number of inclusions

    Time frame: 1 day

Secondary outcomes

  1. Investigate the current molecular epidemiology of resistance in non-M HIV-1 variants in Cameroon

    Proportion of non-M HIV-1 samples characterized genotypically among the samples collected from participants included in the project

    Time frame: 1 Day

Other outcomes

  1. Study the current molecular epidemiology of HIV 1 non-M variant resistance in Cameroon

    Proportion of non-M HIV-1 samples characterized for resistance among the samples collected from participants included in the project

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 7 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → Dec 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 6, 2025
StartEst.
Dec 2026was Jun 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 30, 2025→Dec 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Jun 30, 2025→Dec 2026
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06913959
Collaborators
University Hospital, Rouen, Centre Pasteur du Cameroun
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Dec 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Mariam Gharib, PhD
Contact
mariam.gharib@inserm.fr
0144236442
Elodie Alessandri-Gradt, ParmD PhD
Contact
elodie.alessandri@chu-rouen.fr
+33232855885

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion